Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

TOP PICK

Good way to diversify your portfolio. Nice blend of businesses in terms of pharmaceutical and medical devices. Stock has had a lot of headline problems that has really taken the shares down. Good record of dividend increases and strong balance sheet.

BUY

Diagnostics is probably a good area to consider.

BUY

Great company, great price. Trading at 11X next year's earnings. Dividends on US companies are taxed at the full marginal rate, something like interest rates. As well there is with holding tax charged prior to the receipt of them.

BUY

About one third is Pharma but also has a consumer side and diagnostics. Well diversified. Strong balance sheet and trading at about 11.5-12 times earnings. Good dividend.

DON'T BUY

He is avoiding all US stocks. It’s a great stock for a US account.

BUY

Has some pharma exposure but they have diversification with their consumer and diagnostic businesses. Prefers this to the pure Pharma plays. Good dividend and trades at a multiple of the low teens. Good growth metrics.

BUY

Healthcare companies have not participated in the market run up but, if you are going into a time of market weakness, stocks like this will do well both relatively and absolutely here.

BUY

Has a good presence in emerging markets both in its Pharma business and medical devices. One of the few healthcare firms where management has an overall financial objective. Have raised dividends for 50 some odd years.

DON'T BUY

One of the stronger names in the healthcare space but this might not be the best performing sector. Chart looks quite nice moving along the 50 day moving average. 3% yield with a 40% payout ratio.

PAST TOP PICK

(A Top Pick March 26/09. Up 22.2% excluding dividends.) Trading at one of its lowest historic multiples. 3% yield. The pure pharma companies are suffering from a lack of new drugs but this one is well diversified.

PAST TOP PICK

(Top Pick Feb 23/09, Up 20%) Held it a very long time. They are very unique in that they are a pharma company, a personal care company and medical devices company. They trade at a relatively low PE ratio. A very consistent company that will grow between 10 and 15% yearly.

PAST TOP PICK

(Top Pick Jul 3/09, Up 14.83%) Would still buy.

TOP PICK

Indicative of why investors need to invest outside of Canada. Has a multi-decade record of dividend increases. Regulatory issues are behind it. Low double-digit earnings growth over the next couple of months. Well run. Business: 2/5ths from pharma 2/5ths medical devices and 1/5th consumer health care.

PAST TOP PICK

(A Top Pick Jan 29/09. Up 10.8%.) Not just pharmaceuticals, but a consumer's product company as well. Still likes. Great balance sheet and pays nice dividends.

TOP PICK

Cheap at 14X price to earnings. Gone through a little struggle in the last couple of years because of generic competition but that is basically at an end now and has a pipeline of new drugs that will not be subject to this. Well diversified. Over 3% dividend yield.

Showing 451 to 465 of 626 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)